Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KIT(AY502-3ins) mutation: an in vitro mutagenesis screen for drug-resistance

PURPOSE: While tyrosine kinase inhibitors (TKI) have improved survival in advanced GIST, complete response is rare and most patients eventually fail the first line treatment with imatinib. Sunitinib malate is the only approved 2(nd) line therapy for patients with imatinib-resistant or -intolerant GI...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Guo, Tianhua, Hajdu, Mihai, Agaram, Narasimhan P, Shinoda, Hiroko, Veach, Darren, Clarkson, Bayard D., Maki, Robert G, Singer, Samuel, DeMatteo, Ronald P, Besmer, Peter, Antonescu, Cristina R
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2009
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2783687/
https://ncbi.nlm.nih.gov/pubmed/19861442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1315
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge